— Know what they know.
Not Investment Advice

NSRX

Nasus Pharma Ltd.
1W: +3.4% 1M: -48.5% 3M: -61.7% YTD: -64.1%
$2.76
+0.27 (+10.84%)
After Hours: $2.62 (-0.14, -5.07%)
AMEX · Healthcare · Biotechnology · $23.8M · Alpha Radar Strong Sell · Power 37
Smart Money Score
No convergence signal
Key Statistics
Market Cap$23.8M
52W Range2.4-9.99
Volume249,783
Avg Volume158,900
Beta-1.70
Dividend
Analyst Ratings
No analyst coverage
Company Info
CEODan Teleman
Employees2
SectorHealthcare
IndustryBiotechnology
IPO Date2025-08-13
Yigal Alon 65
Tel Aviv 6744317
IL
97235736632
About Nasus Pharma Ltd.

Nasus Pharma is a clinical-stage specialty pharmaceutical company focused primarily on the development of intranasal drugs to treat emergency medical conditions such as severe allergies, anaphylaxis, and opioid overdose. Their lead products include NS002, an intranasal powder epinephrine nasal spray for type 1 severe allergies and anaphylaxis, and NS001, an intranasal naloxone powder spray for opioid overdose. They use a powder-based intranasal technology that offers rapid drug absorption.

Recent Insider Trades

No insider trades found

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms